Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.55    0.07 (4.38%)
Bid:
1.41
Ask:
1.93
Spread: 0.52 (36.879%)
Market Cap: £5.44m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Holding(s) in Company

20 Oct 2008 09:38

RNS Number : 1922G
Proteome Sciences PLC
20 October 2008
 



Form TR-1 with annex. FSA Version 2.1 updated April 2007

For filings with the FSA include the annex

For filings with issuer exclude the annex 

TR-1: Notifications of Major Interests in Shares

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Proteome Sciences Plc

2. Reason for notification (yes/no)

An acquisition or disposal of voting rights

Yes

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached 

An event changing the breakdown of voting rights

Other (please specify):______________

3. Full name of person(s) subject to notification obligation:

Credit Agricole Cheuvreux International Ltd

4. Full name of shareholder(s) (if different from 3):

5. Date of transaction (and date on which the threshold is crossed or reached if different):

14/10/08

6. Date on which issuer notified:

16/10/08

7. Threshold(s) that is/are crossed or reached:

Less than 3%

8: Notified Details

A: Voting rights attached to shares

Class/type of shares

If possible use ISIN code

GB0003104196

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Less than 3%

Number of shares

4,001,908

Number of voting rights

4,001,908

Number of shares

Number of voting rights

Percentage of voting rights

Direct

Indirect

Direct

Indirect

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date

Exercise/ conversion period/date 

No. of voting rights that may be acquired (if the instrument exercised/converted)

Percentage of voting rights

Total (A+B)

Number of voting rights

Percentage of voting rights

9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable:

SAS Rue La Boétie

Crédit Agricole SA

Calyon SA

Crédit Agricole Cheuvreux SA

Crédit Agricole Cheuvreux International Limited Less than 3%

Proxy Voting:

10. Name of proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14 Contact name:

Gabrielle Burne

15. Contact telephone name:

0207 214 6037

For notes on how to complete form TR-1 please see the FSA website. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLPUGMWUUPRURU
Date   Source Headline
29th Jun 201212:10 pmRNSAGM Statement
7th Jun 20123:10 pmRNSAnnual Financial Report
29th May 20127:00 amRNSFinal Results
30th Apr 20127:00 amRNSTotal Voting Rights
5th Apr 20127:00 amRNSStroke biomarker license to Randox
29th Mar 20125:11 pmRNSBlock Admission Return
28th Mar 20127:00 amRNSCompletion of Alzheimer's Plasma Biomarker Study
19th Mar 201210:00 amRNSEuroHYP EU Grant Award for Stroke
8th Mar 20128:55 amRNSHolding(s) in Company
5th Mar 20127:00 amRNSChange of Adviser
24th Feb 20124:24 pmRNSDirector/PDMR Shareholding
31st Jan 20127:00 amRNSTotal Voting Rights
18th Jan 20127:00 amRNSAdditional Listing
22nd Dec 20117:00 amRNSPromising hits against Alzheimer's Target
24th Nov 20117:00 amRNSNovel In Vitro Assays Developed
8th Nov 20113:39 pmRNSDirector Holdings
7th Oct 20117:00 amRNSBlock Admission Return
30th Sep 20117:00 amRNSInterim Results 2011
11th Aug 20114:35 pmRNSPrice Monitoring Extension
11th Aug 20111:33 pmRNSNotification of Major interest in Shares
9th Aug 20117:00 amRNSProteome Sciences as Preferred Supplier
26th Jul 20117:00 amRNSAppointment of VP Business Development
14th Jul 20117:00 amRNSCollaboration with Buck Institute - biomarket test
7th Jul 20117:00 amRNSCollaboration Agreement
29th Jun 20111:31 pmRNSAGM Statement
28th Jun 20118:12 amRNSDenamic ?6.9m EU Framework Grant
6th Jun 20111:21 pmRNSAnnual Financial Report
27th May 20117:00 amRNSFinal Results
27th May 20117:00 amRNSFinal Results
29th Mar 20117:00 amRNSTakeda Research Contract
28th Mar 20114:38 pmRNSBlocklisting Interim Review
8th Mar 20114:40 pmRNSSecond Price Monitoring Extn
8th Mar 20114:35 pmRNSPrice Monitoring Extension
31st Jan 20117:00 amRNSContract for Biomarker Services with Eisai
10th Jan 20113:39 pmRNSDirector/PDMR Shareholding
23rd Dec 20107:00 amRNSDirectorate Change
20th Dec 20107:00 amRNSResearch Contract
30th Nov 20107:00 amRNSTrading Statement
23rd Nov 201010:30 amRNSBlocklisting Interim Review
23rd Nov 20109:46 amRNSHolding(s) in Company
15th Nov 20107:00 amRNSProteome Sciences form alliance with ICON
14th Oct 20103:00 pmRNSHolding(s) in Company
30th Sep 20107:00 amRNSHalf Yearly Report
28th Sep 20107:00 amRNSStatement re Warranty Claim
23rd Sep 20107:00 amRNSCollaboration with Thermo Fisher
21st Jul 20104:26 pmRNSHolding(s) in Company
13th Jul 20107:00 amRNSProduct Launch
6th Jul 20101:11 pmRNSDirector/PDMR Shareholding
1st Jul 201011:10 amRNSHolding(s) in Company
30th Jun 20104:27 pmRNSResult of AGM,Loan Conversion,Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.